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improvement with a clear increase in cardiac output and decrease
in PCWP. Levosimendan was associated with significantly
improved dyspnea and a trend towards improved fatigue. Inten-
sive care unit stay in levosimendan group is 1 day shorter than
that of the standard treatment group. This shows that the hos-
pitalization costs may be reduced by adopting levosimendan
treatment.
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Background: The aim of the study was to evaluate the role of
multiple biomarkers in short term prognosis of heart failure
patients.
Methods: One hundred cases of heart failure diagnosed by Fra-
mingham’s criterion were taken up. Detailed history, clinical ex-
amination and echocardiographic analysis were done in each
patient. On the day of admission BNP, cTNT, cystatin C and NGAL
levels were estimated. Based on level of each biomarkers, the
patients were divided in two groups for prognostication purpose
for each biomarkers. BNP( > 300pg/ml vs < 300 pg/ml), cTNT ( >
0.03 ng/ml vs <0.03ng/ml and NGAL( > 140mg/l vs <140mg/l) Pa-
tients were followed up for ten days. Improvement or deteriora-
tion in symptoms and NYHA class were noted. Mortality if any
was also noted.
Results: It was observed that there is positive correlation between
clinical deterioration/ mortality and individual levels of BNP,
cTNT and cystatinC based on pre selected cut off value. Combi-
nation of BNP, cTNT and cystatin C all three levels above the cut
off value was associated with 62% of patients showing deteriora-
tion compared to 16% in all these below cut off. Similarly, patients
with combined BNP and cystatin C elevation showed 55% vs 23 %
and BNP and cTNT combined showed 60% vs 28% deterioration in
clinical symptoms.
Conclusions: Combination of BNP, cTNT and Cystatin C is better in
predicting short term outcome in patients of heart failure than
individual biomarkers.
Prevalence of anaemia in chronic heart failure and
contribution of Iron deficiency and renal
dysfunction as underlying cause
Surendra, C.M. Verma, R. Thakur, R.P.S. Bhardwaj, M. Ahmad,
R.K. Bansal, U. Pandey, S.K. Sinha, P. Kumar
Department of cardiology, L.P.S Institute of Cardiology, Kanpur, India
Background: There is growing evidence that anaemia is common
in CHF and may contribute to the high morbidity and mortality
associated with this condition. However, considerable disagree-
ment exists about the prevalence of anemia in CHF patients, with
prevalence rates varying from 9.9% to 55.6%.
Objective: To find the Prevalence of Anaemia in chronic heart
failure and Contribution of Iron deficiency and Renal dysfunction
as underlying cause.
Methods: We studied 200 patients. All the patients were NYHA
class III or IV, 82% being class IV. Haemoglobin concentration of 11
g/dl or less was selected as our cut-off for anaemia. This group
was further subdivided into microcytic, normocytic, and macro-
cytic anaemia. In each of these groups it was noted if any patients
had renal impairment (creatinine >1.5mg/dl) and whether ferritin
was low (<15mcg/l).
Results: Seventy of the 200 patients (35%) selected had a mean
haemoglobin concentration of < 11 g/dl. Of these 70 patients,
20(28.6%) were microcytic, 41(58.6%) were normocytic and
9(12.8%) were macrocytic. In microcytic group, ferritin was low in
12(17.1%) and renal impairment were in 5(7.1%) patients. In nor-
mocytic group, ferritin was low in 7(10%) and renal impairment
were in 23(32.8%) patients. Inmacrocytic group, ferritin was low in
2(2.8%) and renal impairment were in 4 (5.7%) patients. As a
whole, renal impairment was present in 32 patients (45.7%) and
low ferritin was present in 21(30%) patients. The prevalence of
anemia increased from 17.72 % in thosewith a serum creatinine of
< 1.5 mg/dl to 87.5% in those with a serum creatinine of >2.5 mg%.
Conclusion: Anemia is a common finding in patients hospitalized
with CHF and significant numbers of anaemic CHF patients have
some degree of renal insufficiency or iron deficiency.
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Background: The gain in life expectancy due to anthracycline
therapy might be countered by increased mortality due to car-
diotoxicity. The natural history of anthracycline induced cardio-
myopathy (AC-CMP) , remains poorly defined.
Objective: To study clinical profile of patients with AC-CMP and
response to heart failure (HF) therapy.
Methods: This is an analysis of prospectively collected data of
patients with a left ventricular ejection fraction (LVEF) 50 % due
to AC-CMP seen at a tertiary cancer centre in India .Patients with a
minimum follow up of 6 months, a baseline 2Decho,and at least
three 2Dechos after diagnosis of AC-CMP were included. De-
mographic details, comorbidities, cancer diagnosis and treatment
details including dose of anthracycline, treatment for CMP and
response to treatment (ACE inhibitors, beta blockers and or
digoxin) were recorded. Patients were considered responders and
nonresponders according to recovery in LVEF. Univariate and
multivariate analysis of effect of predictor variables on response
to treatment was done. Analyses were performed using PASW
software package (version 18).
Results: 55 patients newly diagnosed with AC-CMP were regis-
tered in 2010-2012. The median dose of doxorubicin was 300mg/
m2. Seven patients had received doxorubicin <¼ 180 mg/m2. Nine
patients (16.4%) presented with grade 4 cardiotoxicity and two
patients (3.6%) with grade 5. Median duration from last dose of
chemotherapy to development of AC-CMP was 5 months. The
median follow up duration was 15 months. 30 (54.5%) were re-
sponders. Age, co morbidities, mediastinal/left chest radiation,
doxorubicin dose, time to development of AC CMP did not affect
the response to treatment in univariate analysis. There was a
higher chance of non response in patients who received doxoru-
bicin more than 200mg/m2 (37%) and patients with grade 4
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